Trade Summary

3 days ago, Doyle Mittie, serving as Chief Medical Officer at Avalo Therapeutics, Inc. (AVTX), sold 1,450 shares at $18.00 per share, for a total transaction value of $26,100.00. Following this transaction, Doyle Mittie now holds 51,776 shares of AVTX.

This sale represents a 2.72% decrease in Doyle Mittie's stake in the company. This is considered a medium-conviction trade.

The trade was executed on Tuesday, June 23, 2026 and publicly disclosed via SEC Form 4 filing on Thursday, June 25, 2026 at 5:24 PM ET, 2 days after the trade was made.

Avalo Therapeutics, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.